Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/176831
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | A novel EPM2A mutation yields a slow progression form of Lafora disease |
Autor: | García-Gimeno, María Adelaida CSIC ORCID; Rodilla-Ramirez, Pilar Natalia; Viana, Rosa CSIC ORCID ; Salas-Puig, Xavier; Brewer, M. Kathryn; Gentry, Matthew S.; Sanz, Pascual CSIC ORCID | Palabras clave: | Epilepsy Gene expression Genetic modifying factor Lafora disease Laforin Malin |
Fecha de publicación: | sep-2018 | Editor: | Elsevier | Citación: | Epilepsy Research 145:169-177 (2018) | Resumen: | Lafora disease (LD, OMIM 254780) is a rare disorder characterized by epilepsy and neurodegeneration leading patients to a vegetative state and death, usually within the first decade from the onset of the first symptoms. In the vast majority of cases LD is related to mutations in either the EPM2A gene (encoding the glucan phosphatase laforin) or the EPM2B gene (encoding the E3-ubiquitin ligase malin). In this work, we characterize the mutations present in the EPM2A gene in a patient displaying a slow progression form of the disease. The patient is compound heterozygous with Y112X and N163D mutations in the corresponding alleles. In primary fibroblasts obtained from the patient, we analyzed the expression of the mutated alleles by quantitative real time PCR and found slightly lower levels of expression of the EPM2A gene respect to control cells. However, by Western blotting we were unable to detect endogenous levels of the protein in crude extracts from patient fibroblasts. The Y112X mutation would render a truncated protein lacking the phosphatase domain and likely degraded. Since minute amounts of laforin-N163D might still play a role in cell physiology, we analyzed the biochemical characteristics of the N163D mutation. We found that recombinant laforin N163D protein was as stable as wild type and exhibited near wild type phosphatase activity towards biologically relevant substrates. On the contrary, it showed a severe impairment in the interaction profile with previously identified laforin binding partners. These results lead us to conclude that the slow progression of the disease present in this patient could be either due to the specific biochemical properties of laforin N163D or to the presence of alternative genetic modifying factors separate from pathogenicity. | Descripción: | 9 páginas, 4 figuras. contiene 2 figuras en material suplementario | Versión del editor: | http://dx.doi.org/10.1016/j.eplepsyres.2018.07.003 | URI: | http://hdl.handle.net/10261/176831 | DOI: | 10.1016/j.eplepsyres.2018.07.003 | ISSN: | 0920-1211 | E-ISSN: | 1872-6844 |
Aparece en las colecciones: | (IBV) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
2018 Epilepsy Res 145-169 Author copy.pdf | 3,9 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
2
checked on 21-abr-2024
SCOPUSTM
Citations
7
checked on 16-abr-2024
WEB OF SCIENCETM
Citations
7
checked on 25-feb-2024
Page view(s)
286
checked on 21-abr-2024
Download(s)
186
checked on 21-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.